OUR STORY

News and Reports

Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.

For media inquiries, contact
Rachel Reinhardt
​Vice President for Communications

T 1 212 450 1582

Ludwig in the news

2019

Apr 29, 2019

STAT
When at Memorial Sloan Kettering, immunotherapy pioneer Nils Lonberg exchanged ideas with Dr. Lloyd Old, former Ludwig Institute Scientific Director and CEO, who believed the immune system could be harnessed against cancer.

Apr 26, 2019

WBUR
In this interview, Ludwig Harvard researcher Arlene Sharpe discusses her career, scientific discoveries and research on the PD-1 pathway, which has led to immunotherapy drugs now being used against more than a dozen types of cancer.

Apr 17, 2019

GEN
In a new eLife study, a team led by Matthew Vander Heiden of Ludwig MIT analyzed the composition of the interstitial fluid that normally surrounds pancreatic tumors and found that its nutrient composition is different from that of the culture medium normally used to grow cancer cells. Growing cancer cells in a culture medium more similar to this interstitial fluid could help researchers better predict how experimental drugs will affect cancer cells.

Apr 16, 2019

HemOnc Today
In this interview, Ludwig Stanford investigator Maximilian Diehn discusses the new urine test method he and his team developed to detect bladder cancer, the benefit of urine-based tests compared with other bladder cancer detection methods, and the likelihood that this approach could become widely adopted.

Apr 03, 2019

CNN
In a panel at the AACR Annual Meeting, Ludwig Johns Hopkins’ Nickolas Papadopoulos discussed the potential for liquid biopsies to help detect cancer earlier, but noted that much more research is needed. He also said that with detection, "it's a difference of thinking proactively rather than reactively” in our response to cancer.

Apr 01, 2019

The Scientist
Heterogeneity in human tumors is key to cancers’ ability to develop immunotherapy resistance. So rather than using mouse models, Ludwig Lausanne Director George Coukos has obtained surgically resected human tumors for testing new immunotherapy drugs. 

 

Mar 06, 2019

The ASCO Post

In this video interview from the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, Ludwig MSK’s Jedd Wolchok discusses the data to date on checkpoint blockades and the rationale for combination therapies and novel agents.

Mar 04, 2019

STAT

In this opinion piece, Ludwig Stanford’s Sam Gambhir argues that we should more aggressively pursue “precision health,” which he defined as ways to prevent disease and, when that isn’t possible, intercept and treat it earlier.

Mar 03, 2019

Global Geneva

Researchers at the Ludwig Center at Harvard have used single-cell technologies and machine learning to create a detailed “atlas of cell states” for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Feb 28, 2019

GenomeWeb

Researchers at the Ludwig Center at Harvard have used single-cell technologies and machine learning to create a detailed “atlas of cell states” for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Feb 26, 2019

GenomeWeb

Bisulfite sequencing has long been the gold standard for analyzing methylation, despite its shortcomings. Now, Ludwig Oxford scientists have developed a new and improved method, called TET-assisted pyridine borane sequencing, or TAPS, to detect chemical modifications to DNA.

Feb 24, 2019

The Guardian

CancerSEEK, a blood test devised by researchers at the Ludwig Center at Johns Hopkins, is one of several methods in development to detect circulating tumor DNA (ctDNA), which may indicate cancer.

Jan 15, 2019

Wall Street Journal
The health-care industry is preparing for a new law, going in effect in 2020, that researchers say will mean more treatments for pediatric cancers. Ludwig Stanford’s Crystal Mackall says “It is an incredibly exciting time…We have lots of drug companies who want to speak with us suddenly. Before, we went hat in hand, cajoling.”